These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 33946916)

  • 41. Tubulin-targeting agents in hybrid drugs.
    Breen EC; Walsh JJ
    Curr Med Chem; 2010; 17(7):609-39. PubMed ID: 20088764
    [TBL] [Abstract][Full Text] [Related]  

  • 42. New microtubule-inhibiting anticancer agents.
    Chen SM; Meng LH; Ding J
    Expert Opin Investig Drugs; 2010 Mar; 19(3):329-43. PubMed ID: 20141350
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Combination of Chinese and Western Medicine to Prevent and Reverse Resistance of Cancer Cells to Anticancer Drugs.
    Sui XB; Xie T
    Chin J Integr Med; 2020 Apr; 26(4):251-255. PubMed ID: 31705451
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Acridone-pyrimidine hybrids- design, synthesis, cytotoxicity studies in resistant and sensitive cancer cells and molecular docking studies.
    Murahari M; Prakash KV; Peters GJ; Mayur YC
    Eur J Med Chem; 2017 Oct; 139():961-981. PubMed ID: 28886509
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Nanoparticle-based drug delivery systems with platinum drugs for overcoming cancer drug resistance.
    Xie P; Wang Y; Wei D; Zhang L; Zhang B; Xiao H; Song H; Mao X
    J Mater Chem B; 2021 Jul; 9(26):5173-5194. PubMed ID: 34116565
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Hypoxia induces universal but differential drug resistance and impairs anticancer mechanisms of 5-fluorouracil in hepatoma cells.
    Li JQ; Wu X; Gan L; Yang XL; Miao ZH
    Acta Pharmacol Sin; 2017 Dec; 38(12):1642-1654. PubMed ID: 28713155
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Anticancer Hybrid Combinations: Mechanisms of Action, Implications and Future Perspectives.
    Domínguez-Martín EM; Díaz-Lanza AM; Faustino CMC
    Curr Pharm Des; 2018; 24(36):4312-4333. PubMed ID: 30636587
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Polymers in the Co-delivery of siRNA and Anticancer Drugs for the Treatment of Drug-resistant Cancers.
    Sun H; Yarovoy I; Capeling M; Cheng C
    Top Curr Chem (Cham); 2017 Apr; 375(2):24. PubMed ID: 28176270
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Towards the overcoming of anticancer drug resistance mediated by p53 mutations.
    Cao X; Hou J; An Q; Assaraf YG; Wang X
    Drug Resist Updat; 2020 Mar; 49():100671. PubMed ID: 31841768
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Tumor Targeting Synergistic Drug Delivery by Self-Assembled Hybrid Nanovesicles to Overcome Drug Resistance.
    Gong MQ; Wu C; He XY; Zong JY; Wu JL; Zhuo RX; Cheng SX
    Pharm Res; 2017 Jan; 34(1):148-160. PubMed ID: 27738951
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Synthesis and Anticancer Cytotoxicity of Azaaurones Overcoming Multidrug Resistance.
    Tóth S; Szepesi Á; Tran-Nguyen VK; Sarkadi B; Német K; Falson P; Di Pietro A; Szakács G; Boumendjel A
    Molecules; 2020 Feb; 25(3):. PubMed ID: 32050702
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Discovery of novel multidrug resistance protein 4 (MRP4) inhibitors as active agents reducing resistance to anticancer drug 6-Mercaptopurine (6-MP) by structure and ligand-based virtual screening.
    Chen Y; Yuan X; Xiao Z; Jin H; Zhang L; Liu Z
    PLoS One; 2018; 13(10):e0205175. PubMed ID: 30321196
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Addressing Drug Resistance in Cancer with Macromolecular Chemotherapeutic Agents.
    Park NH; Cheng W; Lai F; Yang C; Florez de Sessions P; Periaswamy B; Wenhan Chu C; Bianco S; Liu S; Venkataraman S; Chen Q; Yang YY; Hedrick JL
    J Am Chem Soc; 2018 Mar; 140(12):4244-4252. PubMed ID: 29504396
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Multi-Targeted Anticancer Agents.
    Zheng W; Zhao Y; Luo Q; Zhang Y; Wu K; Wang F
    Curr Top Med Chem; 2017 Nov; 17(28):3084-3098. PubMed ID: 28685693
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Overcoming drug resistance in multi-drug resistant cancers and microorganisms: a conceptual framework.
    Avner BS; Fialho AM; Chakrabarty AM
    Bioengineered; 2012; 3(5):262-70. PubMed ID: 22750915
    [TBL] [Abstract][Full Text] [Related]  

  • 56. High-speed screening and quantitative SAR analysis of human ABC transporter ABCG2 for molecular modeling of anticancer drugs to circumvent multidrug resistance.
    Saito H; Hirano H; Ishikawa T
    Mini Rev Med Chem; 2007 Oct; 7(10):1009-18. PubMed ID: 17979803
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Artemisinin-derived hybrids and their anticancer activity.
    Gao F; Sun Z; Kong F; Xiao J
    Eur J Med Chem; 2020 Feb; 188():112044. PubMed ID: 31945642
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Schiff base derived from thiosemicarbazone and anthracene showed high potential in overcoming multidrug resistance in vitro with low drug resistance index.
    Bai J; Wang RH; Qiao Y; Wang A; Fang CJ
    Drug Des Devel Ther; 2017; 11():2227-2237. PubMed ID: 28814831
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance.
    Narayanan S; Cai CY; Assaraf YG; Guo HQ; Cui Q; Wei L; Huang JJ; Ashby CR; Chen ZS
    Drug Resist Updat; 2020 Jan; 48():100663. PubMed ID: 31785545
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical aspects for survivin: a crucial molecule for targeting drug-resistant cancers.
    Singh N; Krishnakumar S; Kanwar RK; Cheung CH; Kanwar JR
    Drug Discov Today; 2015 May; 20(5):578-87. PubMed ID: 25433305
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.